Intra-Articular Drug Delivery for Prosthetic Joint Infection Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prosthetic joint infections (PJIs) are inadequate, leading to recurrent infections, bacterial resistance, and high medical costs due to the lack of standardized antibiotic use regimens, and there is a need for a non-surgical antibacterial treatment method with high efficacy.
Innovation Solution
Administering a therapeutic agent comprising a compound of formula (I) and/or its pharmaceutically acceptable salts, hydrates, solvates, prodrugs, or deuterides to the joint cavity, optionally with dosing frequencies ranging from once daily to once every 7 days, for durations from 1 day to 6 months, via intraarticular injections, potentially with additional components.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical debridement is performed to remove biofilm, then physical disruption of infection is achieved, but recurrent infections occur leading to poor long-term prognosis
Solution Approach 1:
The patent applies preliminary action by administering antibiotics intra-articularly before surgery to reduce bacterial load and disrupt biofilm in advance, making the subsequent surgical debridement more effective and reducing recurrence risk
Solution Approach 2:
The patent implements continuity of useful action through a combined treatment protocol that maintains antibiotic presence both before and after surgery, ensuring continuous antimicrobial pressure throughout the treatment process to prevent recurrence
2Reliability
If adjunctive antibiotic therapy is administered systemically, then bacterial infection is treated, but bacterial resistance and multidrug-resistant organisms develop
Solution Approach 1:
The patent applies local quality by delivering antibiotics directly to the joint cavity through intra-articular injection, creating high local drug concentration at the infection site while maintaining lower systemic levels, thereby reducing selective pressure for resistance development
Solution Approach 2:
The patent uses the joint cavity as an intermediary delivery system to transport antibiotics directly to the infection site, bypassing systemic circulation and reducing the harmful effect of systemic antibiotic exposure on bacterial resistance
3Reliability
If multiple surgical revisions and long-term systemic antibiotic therapy are implemented, then infection control is attempted, but patient quality of life deteriorates and medical costs increase
Solution Approach 1:
The patent reduces the need for multiple surgical revisions by administering preoperative intra-articular antibiotics that reduce bacterial load and inflammation before surgery, improving surgical outcomes and reducing the need for repeat interventions
Solution Approach 2:
The patent introduces intra-articular injection as an intermediary treatment modality that combines the benefits of localized high-dose antibiotic delivery with minimal surgical intervention, improving patient quality of life by avoiding prolonged hospitalization and mobility impairment
Data Source
AI summary
The present application provides a method for preventing or treating a prosthetic joint infection (PJI), or for alleviating PJI-related symptoms. The method comprises: administering a therapeutic agent to a joint cavity of a patient in need thereof, the therapeutic agent comprising a compound represented by formula (I) and/or a pharmaceutically acceptable salt, a hydrate, a solvate, a prodrug, a metabolite, or a deuterated substance thereof.